Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
Eli Lilly's newest medicines for diabetes and obesity, Mounjaro and Zepbound ... Further, Eli Lilly's pipeline features other ...
With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...
After a nurse died after just two weight-loss injections of Mounjaro - which is approved for use on the NHS - here's ...
Obesity has been declared a disease by WHO. It is associated not only with heart disease, diabetes, stroke, gallstones, ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Jim Gaffigan has always used his weight and love for eating as a punchline in his comedy, even going so far to title his 2013 ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Jim Gaffigan exclusively told Us Weekly about using the weight loss drug Mounjaro and why food addiction gets "less sympathy" ...
GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback